Drug Interactions between Adderall XR and ritonavir
This report displays the potential drug interactions for the following 2 drugs:
- Adderall XR (amphetamine/dextroamphetamine)
- ritonavir
Interactions between your drugs
amphetamine ritonavir
Applies to: Adderall XR (amphetamine / dextroamphetamine) and ritonavir
MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations as well as the pharmacologic and adverse effects of amphetamines. The proposed mechanism involves the inhibition of CYP450 2D6, an isoenzyme partially responsible for the metabolic clearance of certain amphetamines. Furthermore, because CYP450 2D6 is genetically polymorphic, variations in amphetamine metabolism across populations may either increase or decrease the risk associated with this interaction. Increased exposure to amphetamines may potentiate the risk of serious adverse reactions such as serotonin syndrome, seizures, psychiatric adverse reactions (e.g., new psychotic or manic symptoms), peripheral vasculopathy (including Raynaud's Phenomenon), and cardiovascular effects (e.g., hypertension, tachycardia). However, data evaluating the interaction are not available.
MANAGEMENT: Caution and closer monitoring for adverse effects are recommended when amphetamines are used concurrently with CYP450 2D6 inhibitors, and a reduction in the initial amphetamine dose should be considered. Patients should be more closely monitored for signs and symptoms of serotonin syndrome, particularly during the initiation of amphetamine therapy and following any dosage increases. Additional caution is advised when amphetamines are coadministered with CYP450 2D6 inhibitors that lower the seizure threshold (e.g., bupropion). Patients should be instructed to notify their healthcare provider if they experience increased amphetamine-related side effects, such as seizures, cardiovascular effects (e.g., hypertension, tachycardia), or symptoms of serotonin syndrome (e.g., mental status changes, autonomic dysfunction like tachycardia or hyperthermia, neuromuscular abnormalities such as hyperreflexia, or gastrointestinal symptoms).
References (14)
- (2023) "Product Information. Amphetamine Sulfate (amphetamine)." Granules Pharmaceuticals Inc.
- (2024) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." Actavis (formerly Abrika Pharmaceuticals LLP)
- (2023) "Product Information. Dexamfetamine (dexamfetamine)." Rosemont Pharmaceuticals Ltd
- (2024) "Product Information. Dexamfetamine (Aspen) (dexamfetamine)." Aspen Pharma Pty Ltd
- (2018) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." AA Pharma Inc
- (2023) "Product Information. Methamphetamine Hydrochloride (methamphetamine)." Mayne Pharma Inc
- (2023) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Alvogen Inc
- (2024) "Product Information. Teva-Lisdexamfetamine (lisdexamfetamine)." Teva Canada Limited
- (2024) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Takeda UK Ltd
- (2024) "Product Information. Vyvanse (lisdexamfetamine)." Takeda Pharmaceuticals Australia Pty Ltd
- (2024) "Product Information. Zyban SR (bupropion)." GlaxoSmithKline Australia Pty Ltd
- (2024) "Product Information. Zyban (bupropion)." GlaxoSmithKline UK Ltd
- (2021) "Product Information. Teva-Bupropion XL (bupropion)." Teva Canada Limited
- (2023) "Product Information. BuPROPion Hydrochloride XL (buPROPion)." Camber Pharmaceuticals, Inc
dextroamphetamine ritonavir
Applies to: Adderall XR (amphetamine / dextroamphetamine) and ritonavir
MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations as well as the pharmacologic and adverse effects of amphetamines. The proposed mechanism involves the inhibition of CYP450 2D6, an isoenzyme partially responsible for the metabolic clearance of certain amphetamines. Furthermore, because CYP450 2D6 is genetically polymorphic, variations in amphetamine metabolism across populations may either increase or decrease the risk associated with this interaction. Increased exposure to amphetamines may potentiate the risk of serious adverse reactions such as serotonin syndrome, seizures, psychiatric adverse reactions (e.g., new psychotic or manic symptoms), peripheral vasculopathy (including Raynaud's Phenomenon), and cardiovascular effects (e.g., hypertension, tachycardia). However, data evaluating the interaction are not available.
MANAGEMENT: Caution and closer monitoring for adverse effects are recommended when amphetamines are used concurrently with CYP450 2D6 inhibitors, and a reduction in the initial amphetamine dose should be considered. Patients should be more closely monitored for signs and symptoms of serotonin syndrome, particularly during the initiation of amphetamine therapy and following any dosage increases. Additional caution is advised when amphetamines are coadministered with CYP450 2D6 inhibitors that lower the seizure threshold (e.g., bupropion). Patients should be instructed to notify their healthcare provider if they experience increased amphetamine-related side effects, such as seizures, cardiovascular effects (e.g., hypertension, tachycardia), or symptoms of serotonin syndrome (e.g., mental status changes, autonomic dysfunction like tachycardia or hyperthermia, neuromuscular abnormalities such as hyperreflexia, or gastrointestinal symptoms).
References (14)
- (2023) "Product Information. Amphetamine Sulfate (amphetamine)." Granules Pharmaceuticals Inc.
- (2024) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." Actavis (formerly Abrika Pharmaceuticals LLP)
- (2023) "Product Information. Dexamfetamine (dexamfetamine)." Rosemont Pharmaceuticals Ltd
- (2024) "Product Information. Dexamfetamine (Aspen) (dexamfetamine)." Aspen Pharma Pty Ltd
- (2018) "Product Information. Dextroamphetamine Sulfate (dextroamphetamine)." AA Pharma Inc
- (2023) "Product Information. Methamphetamine Hydrochloride (methamphetamine)." Mayne Pharma Inc
- (2023) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Alvogen Inc
- (2024) "Product Information. Teva-Lisdexamfetamine (lisdexamfetamine)." Teva Canada Limited
- (2024) "Product Information. Lisdexamfetamine (lisdexamfetamine)." Takeda UK Ltd
- (2024) "Product Information. Vyvanse (lisdexamfetamine)." Takeda Pharmaceuticals Australia Pty Ltd
- (2024) "Product Information. Zyban SR (bupropion)." GlaxoSmithKline Australia Pty Ltd
- (2024) "Product Information. Zyban (bupropion)." GlaxoSmithKline UK Ltd
- (2021) "Product Information. Teva-Bupropion XL (bupropion)." Teva Canada Limited
- (2023) "Product Information. BuPROPion Hydrochloride XL (buPROPion)." Camber Pharmaceuticals, Inc
Drug and food interactions
amphetamine food
Applies to: Adderall XR (amphetamine / dextroamphetamine)
GENERALLY AVOID: Alcohol may potentiate the cardiovascular effects of amphetamines. The exact mechanism of interaction is unknown. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state. The interaction was suspected in a case report of a 20-year-old male who experienced retrosternal chest pain shortly after drinking alcohol and taking a double dose of his amphetamine/dextroamphetamine medication (Adderall 15 mg X 2) to stay alert. The patient had no family history of cardiovascular diseases, and his past medical history was remarkable only for ADHD. Prior to the episode, the patient had not taken his medication for weeks and had been drinking whiskey the previous three nights before going to bed. The patient was diagnosed with myocardial infarction likely secondary to amphetamine-induced coronary vasospasm.
MANAGEMENT: Concomitant use of amphetamines and alcohol should be avoided if possible, especially in patients with a history of heart disease.
References (2)
- Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
- Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M (2009) "Myocardial infarction associated with Adderall XR and alcohol use in a young man." J Am Board Fam Med, 22, p. 197-201
dextroamphetamine food
Applies to: Adderall XR (amphetamine / dextroamphetamine)
GENERALLY AVOID: Alcohol may potentiate the cardiovascular effects of amphetamines. The exact mechanism of interaction is unknown. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state. The interaction was suspected in a case report of a 20-year-old male who experienced retrosternal chest pain shortly after drinking alcohol and taking a double dose of his amphetamine/dextroamphetamine medication (Adderall 15 mg X 2) to stay alert. The patient had no family history of cardiovascular diseases, and his past medical history was remarkable only for ADHD. Prior to the episode, the patient had not taken his medication for weeks and had been drinking whiskey the previous three nights before going to bed. The patient was diagnosed with myocardial infarction likely secondary to amphetamine-induced coronary vasospasm.
MANAGEMENT: Concomitant use of amphetamines and alcohol should be avoided if possible, especially in patients with a history of heart disease.
References (2)
- Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
- Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M (2009) "Myocardial infarction associated with Adderall XR and alcohol use in a young man." J Am Board Fam Med, 22, p. 197-201
ritonavir food
Applies to: ritonavir
ADJUST DOSING INTERVAL: Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.
MANAGEMENT: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.
References (1)
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.